BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline · 22 Jun 2026
Thymosin Alpha-1: The Internationally Approved Immune Peptide in Regulatory Limbo — What the PCAC Vote and Category 2 Removal Mean for Research Procurement
Thymosin alpha-1 is the most clinically validated immune-modulating peptide in the research catalogue — approved as Zadaxin in over 35 countries and evaluated in more than 80 clinical trials. Yet in the United States it remains without FDA approval, was removed from Category 2 in September 2024, and was voted down 4-17 by the PCAC in December 2024. It is not scheduled for the July 2026 PCAC meeting. This briefing examines what that regulatory history means for UK research procurement in…
Read briefing →
Research Pipeline
CJC-1295 and Ipamorelin: The Growth Hormone Pair Left Out of the July 2026 PCAC — What the Regulatory Limbo Means for Research Procurement
CJC-1295 and Ipamorelin are among the most widely studied growth hormone secretagogue peptides, yet they occupy a regulatory position distinct from the twelve substances currently heading for the July 2026 PCAC review. A 2024 advisory committee already voted against their inclusion on the 503A Bulks List, and neither compound appears on either scheduled PCAC agenda. Research procurement teams need to understand what that means for legitimate sourcing and laboratory use.
21 Jun 2026
Research Pipeline
GHK-Cu: The Copper Tripeptide Caught Between Two Regulatory Categories — and What It Means for Research Procurement
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) holds a singular position in the 2026 peptide regulatory landscape: it is the only compound among the twelve removed from FDA Category 2 that has simultaneously been withdrawn from Category 1, leaving it in a distinct limbo ahead of a scheduled PCAC review before February 2027. This briefing outlines the compound's biochemistry, the current state of clinical evidence, and the procurement implications for UK research laboratories.
20 Jun 2026
Research Pipeline
BPC-157: What the 2026 Evidence Review, New Human Trial and Dual Regulatory Scrutiny Mean for Research Procurement
A March 2026 peer-reviewed review reinforces BPC-157's preclinical tissue-repair profile, yet human clinical data remain sparse and a newly registered controlled trial is the first to formally test the peptide in a musculoskeletal injury population. Meanwhile, the MHRA has opened investigations into UK clinics making unlicensed therapeutic claims, and the FDA is set to scrutinise the compound at its July 2026 PCAC meeting. Research-procurement teams need a clear picture of what is known, what…
19 Jun 2026
Regulatory & Policy
FDA's Proposed Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide from the 503B Bulks List: What the 29 June Comment Deadline Means for Research Procurement
The FDA has proposed permanently barring 503B outsourcing facilities from bulk-compounding semaglutide, tirzepatide and liraglutide, finding no clinical need for their inclusion on the 503B Bulks List. With the public comment window closing on 29–30 June 2026, research procurement professionals should understand what the rule would foreclose, which legal pathways remain, and how the diverging US regulatory posture contrasts with the UK framework.
18 Jun 2026
Regulatory & Policy
Semax and Epitalon at the July 2026 PCAC: What the Day-Two Agenda and Dual June Deadlines Mean for Research Procurement
Two high-profile peptides — Semax and Epitalon — are scheduled for FDA Pharmacy Compounding Advisory Committee review on 24 July 2026. With oral-comment requests due 30 June and a parallel 503B GLP-1 exclusion deadline on 29 June, UK procurement teams face a concentrated window of US regulatory activity that will shape licit supply chains for both compounds.
17 Jun 2026
Regulatory & Policy
MHRA Approves Oral Semaglutide for Weight Management: What the UK's First GLP-1 Pill Means for Research Procurement
The MHRA approved oral semaglutide 25 mg (Wegovy pill) for weight management on 11 June 2026, making it the first oral GLP-1 receptor agonist licensed for obesity in the UK. Coming within weeks of the FDA's approval of orforglipron (Foundayo) and new Phase 3 data for retatrutide, the decision reshapes the incretin research landscape and has direct implications for UK labs procuring GLP-1 reference compounds.
15 Jun 2026
Research Pipeline
TB-500: What the First Human RCT and 2026 Regulatory Reclassification Mean for Research Procurement
A Phase 1/2 randomised controlled trial of TB-500 in adults with stable cardiovascular disease — the first interventional human study of the 17-amino acid fragment specifically — began enrolment in early 2026. Simultaneously, the February 2026 FDA reclassification placed TB-500 in the 503A Category 2 prohibited list, reshaping how UK and US research labs can legitimately source the compound.
13 Jun 2026
Industry & Community
The 2026 Oral Peptide Wave: What Approved Drugs, NDA Filings and Major Funding Rounds Mean for Research Procurement
A convergence of approvals, regulatory filings and investor capital is reshaping the oral peptide landscape in 2026. From orforglipron's April FDA clearance to Merck's NDA submission for an oral macrocyclic PCSK9 inhibitor and two oversubscribed platform financing rounds, the field is advancing along lines that will directly influence which peptide classes attract the most research attention — and procurement spend — over the next three years.
12 Jun 2026
Industry & Community
Peptide Platforms Attract Record Capital: What the Parabilis $670M IPO and 2026 Investment Surge Mean for Research Procurement
Parabilis Medicines closed the largest-ever venture-backed biotech IPO on 9 June 2026, raising $670 million for its Helicon helix-shaped peptide platform. Alongside a string of peptide-focused funding rounds, the capital surge signals a structural shift in how investors view peptide drug discovery — with direct implications for supply chains, platform technologies, and procurement priorities at UK research labs.
11 Jun 2026
Research Pipeline
GLP-1 Receptors and Oncology: What the ASCO 2026 Evidence Cluster Means for Research Procurement
A cluster of five real-world studies presented at the 2026 American Society of Clinical Oncology Annual Meeting has elevated GLP-1 receptor agonists as a serious subject of oncology research, with signals across metastatic progression, breast cancer prevention, and immune checkpoint inhibitor outcomes. For research-procurement teams, the findings point to growing demand for characterised GLP-1 peptide material beyond metabolic applications.
10 Jun 2026
Pharma & GLP-1
ADA 86th Scientific Sessions: What the June 2026 Phase 3 Wave Means for Peptide and GLP-1 Research Procurement
The American Diabetes Association's 86th Scientific Sessions closed in New Orleans on 8 June 2026 with pivotal Phase 3 data for retatrutide, orforglipron, and CagriSema, alongside a formal revision to the ADA Standards of Care that repositions cardiovascular and kidney risk reduction as co-primary treatment goals. The meeting reshapes the near-term clinical and procurement landscape for GLP-1 and next-generation peptide-based therapeutics.
09 Jun 2026